Melvin K. Spigelman - 24 Mar 2022 Form 3 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Director
Signature
/s/ Lucy Day, Attorney-in-Fact for Melvin K. Spigelman
Issuer symbol
ANTX
Transactions as of
24 Mar 2022
Net transactions value
$0
Form type
3
Filing time
24 Mar 2022, 21:27:24 UTC
Next filing
16 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ANTX Stock Option (right to buy) 24 Mar 2022 Common Stock 16,941 $9.31 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest as follows: 1/36th of the shares shall vest monthly over three years from February 7, 2022, subject to the Reporting Person's continuous service as of such date.

Remarks:

Exhibit 24 - Power of Attorney